News in Brief
Pharmacology - 08:30
Novartis receives EC approval for new Xolair indication to treat severe chronic rhinosinusitis with nasal polyps
Novartis receives EC approval for new Xolair indication to treat severe chronic rhinosinusitis with nasal polyps
Pharmacology - Aug 5
Novartis announces NEJM publication of Phase III ASCLEPIOS trials demonstrating superior efficacy of ofatumumab in patients with relapsing multiple sclerosis
Novartis announces NEJM publication of Phase III ASCLEPIOS trials demonstrating superior efficacy of ofatumumab in patients with relapsing multiple sclerosis
wire - news in brief
Category
Results 1 - 50 of 450.
Novartis announces NEJM publication of Phase III ASCLEPIOS trials demonstrating superior efficacy of ofatumumab in patients with relapsing multiple sclerosis
Ofatumumab is a targeted B-cell therapy that delivers superior efficacy with a similar safety profile when compared with teriflunomide, a commonly prescribed oral treatment for multiple sclerosis 1
Ofatumumab is a targeted B-cell therapy that delivers superior efficacy with a similar safety profile when compared with teriflunomide, a commonly prescribed oral treatment for multiple sclerosis 1
Novartis announces Kymriah meets primary endpoint at interim analysis of pivotal study in follicular lymphoma
Global ELARA trial demonstrated clinically meaningful benefit in patients with relapsed or refractory (r/r) follicular lymphoma (FL) as measured by complete response rate Kymriah previously receive
Global ELARA trial demonstrated clinically meaningful benefit in patients with relapsed or refractory (r/r) follicular lymphoma (FL) as measured by complete response rate Kymriah previously receive
Novartis Cosentyx receives EU approval for first-line systemic treatment in pediatric psoriasis
EU approval is based on two Phase III studies showing Cosentyx provides fast and strong skin clearance, along with significant improvement in quality of life and a favorable safety profile 1 Modera
EU approval is based on two Phase III studies showing Cosentyx provides fast and strong skin clearance, along with significant improvement in quality of life and a favorable safety profile 1 Modera
Novartis receives Piqray approval in Europe - the first and only targeted medicine for HR+/HER2- advanced breast cancer with a PIK3CA mutation
Piqray (alpelisib) is the only treatment approved specifically to address PIK3CA mutation, underscoring Novartis commitment to reimagining cancer care Approval based on SOLAR-1 Phase III trial showing Piqray plus fulvestrant nearly doubled median PFS (11.0 vs.
Piqray (alpelisib) is the only treatment approved specifically to address PIK3CA mutation, underscoring Novartis commitment to reimagining cancer care Approval based on SOLAR-1 Phase III trial showing Piqray plus fulvestrant nearly doubled median PFS (11.0 vs.
Olga Fink develops artificial intelligence algorithms for industrial assets, rolling stock and power plants.
Immunoprotein impairs Sars-Cov-2
An international team with researchers of the Institute of Virology and Immunology (IVI) of the University of Bern and the Swiss Federal Food Safety and Veterinary Office (FSVO) showed that an endogenous protein prevents the virus from fusing with host cells.
An international team with researchers of the Institute of Virology and Immunology (IVI) of the University of Bern and the Swiss Federal Food Safety and Veterinary Office (FSVO) showed that an endogenous protein prevents the virus from fusing with host cells.
In Agatha Christie's novel The Pale Horse, the victims die of thallium poisoning.
Researchers at the University of Basel have a vision: an individually configurable robot will revolutionize surgical procedures and provide numerous benefits for patients.
New Novartis analysis shows wet AMD patients achieved sustained fluid control faster with Beovu versus aflibercept
A post-hoc analysis of the HAWK and HARRIER trials presented at ASRS showed >=50% of patients achieved sustained retinal dryness by weeks 8 and 4 with Beovu and by weeks 12 and 8 with aflibercept,
A post-hoc analysis of the HAWK and HARRIER trials presented at ASRS showed >=50% of patients achieved sustained retinal dryness by weeks 8 and 4 with Beovu and by weeks 12 and 8 with aflibercept,
HES-SO en bref HES-SO Actualités HES-SO Quatorze projets de collaboration HES-SO - Instituts polytechniques portugais L'appel à projets d'impulsion lancé dan
"Ticino a te", bringing local produce closer to you also thanks to USI
The Osservatorio dello sviluppo territoriale (OST) (Observatory of Territorial Development), based at USI Academy of Architecture, has developed, in collaboration with Centro di Competenze Agroalimen
The Osservatorio dello sviluppo territoriale (OST) (Observatory of Territorial Development), based at USI Academy of Architecture, has developed, in collaboration with Centro di Competenze Agroalimen
An academic career in Finance, from Lugano to Lisbona
Lugano, St. Gallen, Barcelona, Lugano, New York, Lugano, Lisbon... these are the steps along the academic career path of Virginia Gianinazzi, who has recently obtained her PhD in finance at U
Lugano, St. Gallen, Barcelona, Lugano, New York, Lugano, Lisbon... these are the steps along the academic career path of Virginia Gianinazzi, who has recently obtained her PhD in finance at U
Lithium-ion batteries contain salts rich in fluorine, which decompose in humid air to toxic, highly corrosive hydrogen fluoride. The hazardous nature of this substance makes recycling more difficult and more expensive. A research project entitled "Fluoribat" is now being launched at Empa to solve this problem.
No year since weather records began was as hot and dry as 2018. A first comprehensive analysis of the consequences of this drought and heat event shows that central European forests sustained long-term damage.
The use of drones in global health settings has rapidly evolved in the past years. As drone technology continues to expand beyond the military and recreational sectors, it is foreseen that it will have a significant role to play in healthcare delivery.
An international expert group led by Mathias Wirth, Professor of Systematic Theology and Ethics at the University of Bern, has developed recommendations for avoiding triage of COVID-19 patients in extreme situations.
Summer Series: Science as a vocation. Christophe Galland, the head of EPFL's Laboratory of Quantum and Nano-Optics, believes that teaching and research are inextricably linked.
New data from phase IIIb study reinforces safety profile of Roche’s Hemlibra in people with haemophilia A
Second interim analysis of the STASEY study, including data from 193 patients, consistent with results from phase III HAVEN studies, with no new safety signals identified 1,2,3 STASEY is the largest
Second interim analysis of the STASEY study, including data from 193 patients, consistent with results from phase III HAVEN studies, with no new safety signals identified 1,2,3 STASEY is the largest
We continue our journey to discover the USI Faculty of Biomedical Sciences with Marta Fadda, post-doctoral researcher and lecturer, with whom we talk about social and cultural patterns, medical ethic
"Science Wire" gives access to latest science news from universities, research centers and R&D companies.Add this page to your bookmarks
News in Brief
Pharmacology - 08:30
Novartis receives EC approval for new Xolair indication to treat severe chronic rhinosinusitis with nasal polyps
Novartis receives EC approval for new Xolair indication to treat severe chronic rhinosinusitis with nasal polyps
Pharmacology - Aug 5
Novartis announces NEJM publication of Phase III ASCLEPIOS trials demonstrating superior efficacy of ofatumumab in patients with relapsing multiple sclerosis
Novartis announces NEJM publication of Phase III ASCLEPIOS trials demonstrating superior efficacy of ofatumumab in patients with relapsing multiple sclerosis